Draig Therapeutics
8 known investors
Draig Therapeutics is a clinical-stage biotech company developing neuromodulator therapies for neuropsychiatric disorders such as major depressive disorder. Its lead program, DT-101, is a Phase 2 AMPA receptor potentiator, and it is also advancing selective GABAA receptor modulators.
BiotechDeep TechDigital Health
Investors · 8
Access BiotechnologyNew York City
Canaan PartnersStamford · $500K – $20M
Sanofi VenturesCambridge · $5M
SV Health InvestorsBoston · $1M – $20Mvia Charles Dunn · led
British Business BankreportedSheffield
Janus Henderson InvestorsreportedNew York
Also in the syndicate · 2
Deep Track CapitalleadJefferson Life Sciences
Funding
SEC filings, press & company announcements$65M disclosed across 1 round · 2026
- $65MSeries BJul 2026 · 2 sources
Deep Track Capital (lead), British Business Bank, Janus Henderson Investors, Jefferson Life Sciences, Marshall Wace
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Draig Therapeutics do?
- Draig Therapeutics is a clinical-stage biotech company developing neuromodulator therapies for neuropsychiatric disorders such as major depressive disorder. Its lead program, DT-101, is a Phase 2 AMPA receptor potentiator, and it is also advancing selective GABAA receptor modulators.
- Who are Draig Therapeutics's investors?
- Draig Therapeutics's investors include Access Biotechnology, Canaan Partners, Sanofi Ventures, SV Health Investors, British Business Bank, Janus Henderson Investors.
- How much funding has Draig Therapeutics raised?
- Draig Therapeutics has disclosed $65M raised across 1 round.